This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Recombinant Equine Interleukin-17 (IL17), N-His
Product Overview
BioVenic's Recombinant Equine Interleukin-17 (IL17), N-His is a recombinant protein expressed from E.coli expression system. Its predicted molecular weight is 18.6 kDa. The purity is greater than 90% (SDS-PAGE). The endotoxin level is <1 EU/μg (LAL). It can be used as a positive control or as an immunogen.
Specifications
Target Information
Interleukin 17 is encoded by the IL17 gene in horses. IL17 is produced by CD4+ T helper 17 and other cell types such as gamma-delta T cells, natural killer cells, lymphoid tissue inducer cells, macrophages, eosinophils and neutrophils. Research has shown that IL17 directly activates equine neutrophils at 24 hours and that the induced expression of IL8 is not attenuated by glucocorticoids.
Shipping and Storage
This product is shipped with dry ice. Avoid repeated freezing and thawing. Store for 4 weeks at 2-8°C, for 12 months at -80°C.
Documents
The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.
User Note
- Always centrifuge tubes before opening. Avoid mixing by vortexing or pipetting. Reconstitute in 10 mM PBS (pH 7.4) to a concentration of 0.1-1.0 mg/mL. Aliquote the reconstituted solution to minimise freeze-thaw cycles.
References
- Murcia, R. Y. et al. The Interleukin-17 Induced Activation and Increased Survival of Equine Neutrophils Is Insensitive to Glucocorticoids. PloS one. 2016, 11: e0154755.